after providing informed consent, you will undergo baseline medical assessments and be assigned randomly to receive either nxt007 or emicizumab prophylaxis.

you will have a physical examination, laboratory tests, and complete a quality of life questionnaire to establish baseline values.

you will receive the assigned study drug by subcutaneous injection.

the dose and injection frequency are defined by the study protocol and are not disclosed here; the medication will be administered throughout the study period.

from this visit onward, the primary endpoint, the annualized number of treated bleeds (abr), will be recorded until the clinical cutoff date.

you will continue to record any bleeds and receive study medication as scheduled.

you will attend scheduled visits (typically monthly) for safety assessments, injection training, and collection of blood samples.

blood samples will be analyzed for plasma concentration of the study drug and for the presence of anti‑drug antibodies.

adverse events, injection‑site reactions, and any signs of thrombotic complications will be evaluated at each visit.

you will complete the quality of life questionnaire again to assess changes since baseline.

throughout the trial you will be instructed to report any adverse events, including severe hypersensitivity, anaphylaxis, or thromboembolic events.

the study team will track the number of injections and dose per bleed of any additional coagulation factors or bypassing agents you may require.

at the end of the study period, you will undergo final assessments, including a final quality of life questionnaire, blood sampling for drug concentration and antibody testing, and a summary of bleeding episodes.

the study medication will be discontinued after this visit.